Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04), Zacks reports. The firm had revenue of $36.90 million for the quarter, compared to analyst estimates of $46.94 million. Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%.
Here are the key takeaways from Akebia Therapeutics’ conference call:
- The 2,116-patient VOICE trial showed a 10% reduction in hospitalizations with Vafseo versus ESA and met its primary endpoint for superiority, with no significant mortality difference. Akebia also reported VOCAL topline results showing Vafseo was non-inferior to ESA in maintaining hemoglobin with three-times-weekly dosing.
- Vafseo patients on therapy grew about 140% year over year, but Q3 product revenue rose only 3% to $14.8 million. Akebia attributed the gap to customer inventory drawdowns tied to lower-than-expected dosing and dialysis attendance, estimating underlying Q3 end-user demand at $19–$20 million.
- As Vafseo’s separate TDAPA reimbursement ends on January 1, 2027, Akebia expects annual therapy costs to fall to roughly $1,000–$1,500, reflecting lower ESA prices, dosing, and compliance. DaVita plans a gradual rollout, while Fresenius remains interested but is expected to move more slowly.
- Q3 total revenue fell to $36.9 million from $58.8 million a year earlier, largely as Auryxia revenue dropped to $20 million from $42.5 million amid generic competition and pricing pressure. Akebia recorded a $14.4 million net loss, compared with $0.5 million of net income in Q3 2025.
- Akebia’s phase II trials of praliciguat in FSGS and ebribafusp across C3G, IgAN, and lupus nephritis are enrolling; initial ebribafusp data are expected in 2027, while no praliciguat data timing was provided. The company ended the quarter with $159.3 million in cash and said it expects to fund its current operating plan for at least two years.
Akebia Therapeutics Price Performance
Shares of Akebia Therapeutics stock opened at $0.43 on Friday. Akebia Therapeutics has a 12 month low of $0.42 and a 12 month high of $2.11. The company has a current ratio of 1.43, a quick ratio of 1.35 and a debt-to-equity ratio of 0.99. The business’s fifty day simple moving average is $0.82 and its 200 day simple moving average is $1.13.
Wall Street Analysts Forecast Growth
Several research firms recently commented on AKBA. Weiss Ratings cut Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. BTIG Research reiterated a “buy” rating and issued a $4.00 target price on shares of Akebia Therapeutics in a report on Tuesday, September 15th. Westpark Capital started coverage on Akebia Therapeutics in a research note on Tuesday, September 8th. They issued a “buy” rating and a $4.50 price target on the stock. Wall Street Zen upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 1st. Finally, Leerink Partners downgraded Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 price target on the stock. in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $3.90.
Read Our Latest Report on AKBA
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company’s primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.
Akebia’s key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body’s natural production of erythropoietin and support red blood cell formation.
Featured Stories
- Five stocks we like better than Akebia Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
